Navigation Links
Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
Date:12/13/2011

NEW YORK, Dec. 13, 2011 /PRNewswire/ -- Synergy Pharmaceuticals, Inc. (Nasdaq: SGYPD, SGYPU), a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, announced today that it has filed a lawsuit in New York State Supreme Court against Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie. 

The lawsuit alleges that after European patent 1,379,224 was granted to Synergy but prior to issuance, Ironwood and Dr. Currie opposed the patent before the European Patent Office and presented to the European Patent Office and the United States Patent and Trademark Office, data and arguments that were false, contradictory, inaccurate and misleading.  In its complaint, Synergy accuses Ironwood and Dr. Currie of, among other things, unfair competition, fraud and unjust enrichment and seeks $500 million in actual and punitive damages.

About Synergy Pharmaceuticals, Inc.

Synergy is a biopharmaceutical company focused on the development of new drugs to treat gastrointestinal disorders and diseases. Synergy's proprietary drug candidate plecanatide is a synthetic analog of the human gastrointestinal hormone uroguanylin, and functions by activating the guanylate cyclase C receptor on epithelial cells of the GI tract. Synergy completed a Phase I study of plecanatide in healthy volunteers and a Phase IIa clinical trial in patients to treat chronic idiopathic constipation (CIC) patients. In October 2011, Synergy initiated dosing of patients in a major Phase II/III clinical trial of plecanatide in CIC patients. Plecanatide is also being developed to treat constipation-predominant irritable bowel syndrome, with the first trial in IBS-C patients planned for 2012. Synergy's second GC-C agonist SP-333 is currently in pre-clinical development to treat inflammatory bowel diseases. More information is available at http://www.synergypharma.com.  


'/>"/>
SOURCE Synergy Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Synergy Business Solutions Acquires the Microsoft Dynamics SL Practice of Congruent Software, Inc.
2. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
3. VioQuest Pharmaceuticals, Inc Q2/08 Review Issued by Scimitar Equity, LLC
4. Rib-X Pharmaceuticals, Inc. Announces Formation of Clinical Advisory Board
5. Pacira Pharmaceuticals, Inc. Adds Experienced Physician Dr. David St. Peter to Leadership Team
6. Transcept Pharmaceuticals, Inc. to Present at the Natixis Bleichroeder Second Annual Hidden Gems Conference
7. Transdel Pharmaceuticals, Inc. Retains The Investor Relations Group
8. Chemical Engineering Conference Highlights Energy, Biomedicine, Pharmaceuticals, Sustainability and Centennial
9. Alseres Pharmaceuticals, Inc. Reports Third Quarter 2008 Operational and Financial Results
10. Johnson & Johnson Completes Acquisition of Omrix Biopharmaceuticals, Inc.
11. Alseres Pharmaceuticals, Inc. Announces $1 Million Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... ComplianceOnline’s Medical Device Summit is back for ... June 2018 in San Francisco, CA. The Summit brings together current and former FDA ... board directors and government officials from around the world to address key issues in ...
(Date:10/11/2017)... a leading provider of patient support solutions, has announced the ... which will launch this week. The VMS CNEs will address ... enhance the patient care experience by delivering peer-to-peer education programs ... to help women who have been diagnosed and are being ... ...
(Date:10/11/2017)... ... ... Disappearing forests and increased emissions are the main causes of the evolving ... those living in larger cities are affected by air pollution related diseases. , That ... countries globally - decided to take action. , “I knew I had to take ...
(Date:10/11/2017)... ... October 11, 2017 , ... Singh ... orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator of ... SBT-100 is able to cross the cell membrane and bind intracellular STAT3 and ...
Breaking Biology Technology:
(Date:6/23/2017)... N.Y. and ITHACA, N.Y. ... ) and Cornell University, a leader in dairy research, ... with bioinformatics designed to help reduce the chances that ... With the onset of this dairy project, Cornell University ... Consortium for Sequencing the Food Supply Chain, a food ...
(Date:5/23/2017)...  Hunova, the first robotic gym for the rehabilitation and functional motor ... Genoa, Italy . The first 30 robots will be ... USA . The technology was developed and patented at the ... spin-off Movendo Technology thanks to a 10 million euro investment from entrepreneur ... ...
(Date:5/16/2017)... DALLAS , May 16, 2017   ... for health organizations, and MD EMR Systems ... certified development partner for GE, have established a ... Patient Portal product and the GE Centricity™ products, ... Centricity EMR. These new integrations ...
Breaking Biology News(10 mins):